The patients with fatal HER2-negative (HER2 0) primary tumors had a much larger metastatic tumor burden than those with fatal HER2-low tumors, which may explain the fatal outcome in HER2 0 cases. The gene discussed is ERBB2; the disease is metastatic neoplasm.